Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • BlueRock Therapeutics

    - PMLiVE

    Mission Therapeutics advances Parkinson’s disease candidate

    The company also received a grant from the Michael J. Fox Foundation and Parkinson’s UK

    - PMLiVE

    PhotoPharmics’ new advisory board to guide launch of FDA Breakthrough device for Parkinson’s

    The US-based company develops light-based therapies for neurodegenerative conditions

    - PMLiVE

    TRIMTECH Therapeutics establishes Scientific Advisory Board

    Alessio Ciulli has been appointed as Chair of the board

    - PMLiVE

    Roche shares promising data from Alzheimer’s disease development portfolio

    The company is planning to initiate phase 3 studies of trontinemab in early AD this year

    Bayer symbol

    Bayer’s Kerendia granted FDA approval for new heart failure indication

    Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

    - PMLiVE

    UKDRI researchers to evaluate new blood test for neurodegenerative disease diagnosis

    It is hoped that the test could be available for widespread UK use in the coming years

    Bayer symbol

    Bayer’s Vitrakvi receives full FDA approval for NTRK gene fusion-positive tumours

    The US regulator first approved the TRK inhibitor in 2018 under its accelerated approval pathway

    - PMLiVE

    GSK and ABL Bio enter neurodegenerative disease agreement worth over £2bn

    The licensing deal will give GSK access to ABL Bio's blood-brain barrier shuttle platform

    - PMLiVE

    Sanofi’s investigational MS treatment tolebrutinib granted FDA priority review

    Approximately 2.9 million people worldwide are living with the neurodegenerative disease

    - PMLiVE

    GSK to explore link between Shingrix and dementia risk in new UK research collaboration

    More than 55 million people worldwide are currently living with the neurodegenerative disease

    - PMLiVE

    FDA grants RMAT designation to AskBio’s Parkinson’s gene therapy candidate

    The progressive neurodegenerative disease affects more than ten million people worldwide

    Bayer symbol

    Bayer UK launches digital educational hub to improve menopause support

    An estimated 13 million women in the UK are currently perimenopausal or menopausal

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links